Cortical Disarray Measurement (CDM) is a platform technology designed to assess Alzheimer’s disease at the cellular level, in contrast to simple volumetric methods

We extract measurements directly from standard MRI/DTI data to provide an index linked to the micro-anatomical health of patients' brains

Our CDM software device aspires to offer unique insights into the point at which the disease materialises in the anatomy of the cerebral cortex

Our CDM Technology can identify the location and pattern of change in grey matter quality in order to pursue new levels of diagnostic certainty beyond simple measures of quantity